SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                 FORM 10-KSB/A

                 [x] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF
                      THE SECURITIES EXCHANGE ACT OF 1934

                    FOR THE FISCAL YEAR ENDED APRIL 30, 2004

                                       or

                [_] TRANSITION REPORT UNDER SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

                             Commission File Number

                         LARREA BIOSCIENCES CORPORATION.

           (Name of small business issuer as specified in its charter)

                   NEVADA                               680507505
       (State or other jurisdiction of               (I.R.S. Employer
        incorporation or organization)             Identification Number)

                               c/o David Kalenuik
                               400-55 Water Street
                       Vancouver, British Columbia V6B1A1

                              Phone: (604) 899-7977
                               Fax: (604) 899-6109

         SECURITIES REGISTERED UNDER SECTION 12(b) OF THE EXCHANGE ACT:

                                     (None)

         SECURITIES REGISTERED UNDER SECTION 12(g) OF THE EXCHANGE ACT:

                         COMMON STOCK, $.0001 PAR VALUE
                                (TITLE OF CLASS)

Check  whether the issuer (1) filed all reports  required to be filed by Section
13 or 15(d) of the  Exchange  Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports),  and (2) has been
subject to such filing requirements for the past 90 days. Yes [x] No [ ]

Check if disclosure  of delinquent  filers in response to Item 405 of Regulation
S-B, is not contained in this form and no disclosure  will be continued,  to the
best of registrant's  knowledge,  in definitive proxy or information  statements
incorporated  by reference  in Part III of this Form 10-KSB or any  amendment to
the Form 10-KSB. [ ]

Registrant's had no revenues for the fiscal year ended April 30, 2004.

As of July 26, 2004,  Registrant had  16,230,760  shares of its $.0001 par value
Common Stock issued and outstanding with an aggregate market value of the common
stock held by  non-affiliates of approximately  $8,379,798.  This calculation is
based upon the closing sales price of $1.05 per share on August 9, 2004.

                       DOCUMENTS INCORPORATED BY REFERENCE

                                     (None)

Transitional Small Business Disclosure Format (Check one): Yes [ ]; No X

                                       1
<PAGE>


                   TABLE OF CONTENTS AND CROSS REFERENCE SHEET

PART I

PAGE

Item 1       Description of Business                                          3
Item 2       Description of Property                                          6
Item 3       Legal Proceedings                                                6
Item 4       Submission of Matters to a Vote of Security Holders              6

PART II

Item 5       Market for Common Equity and Related Stockholder Matters         7
Item 6       Management's Discussion and Analysis and Plan of Operations      7
Item 7       Financial Statements                                             9
Item 8       Changes in and Disagreements with Accountants on
             Accounting and Financial Disclosure                              9
Item 8A      Controls and Procedures

PART III

Item 9       Directors, Executive Officers, Promoters and Control Persons;
             Compliance with Section 16(a) of the Exchange Act                9
Item 10      Executive Compensation                                          10
Item 11      Security Ownership of Certain Beneficial Owners and
             Management                                                      11
Item 12      Certain Relationships and Related Transactions                  11

PART IV

Item 13      Exhibits and Reports on Form 8-K                                11


                                       2
<PAGE>


                                     PART I

This Form 10-KSB contains forward looking statements relating to the development
of the Company's products and services and future operation results, including
statements regarding the Company that are subject to certain risks and
uncertainties that could cause actual results to differ materially from those
projected. The words "believe," "expect," "anticipate," "intend," variations of
such words, and similar expressions, identify forward looking statements, but
their absence does not mean that the statement is not forward looking. These
statements are not guarantees of future performance and are subject to certain
risks, uncertainties and assumptions that are difficult to predict. Factors that
could affect the Company's actual results include the progress and costs of the
development of products and services and the timing of the market acceptance.

ITEM 1 - BUSINESS

GENERAL

Larrea Biosciences Corporation (F/K/A Sonic Media Corporation, "LBC" or the
"Company") entered into an agreement dated March 26, 2004 to acquire Global
Botanics International, Inc. ("GBI") in March, but only recently issued shares
to the selling shareholders of GBI. As this transaction was consummated after
the end of the Company's April 30, 2004 fiscal year end, the financial
information contained in this document does not reflect GBI operations. The
closing of the GBI transaction, puts the Company, through GBI, in the business
of harvesting, producing and licensing Virastatin(TM), a multifunctional
ingredient produced according to patented extraction and purification
technologies. Because Virastatin(TM) has proven antiviral, anti-inflammatory,
antimicrobial and antioxidant properties, the ingredient is beneficial in a wide
variety of health and consumer products. Current arrangements support the
purchase of Virastatin for inclusion in private labeled products. GBI's product
is marketed and sold in the U.S. and Canada by LarreaRx, Inc. To date, LarreaRx,
Inc. has licensed the right to market and sell Virastatin-based dietary
supplement and topical cosmetic products in the U.S. and Canada. Virastatin(TM)
is the key active ingredient in the product lines sold under the tradenames
Shegoi(TM) and Virox(TM). Shegoi(TM) products are marketed through direct
marketing channels and Virox(TM) products are already being marketed through
retail chain outlets in Canada and USA.

In addition to the profits generated from the sale of Virastatin(TM) ingredient,
GBI may earn royalties on all products sold by licensees. GBI plans to penetrate
the global market through similar licensing arrangements with multiple marketing
partners, who specialize in marketing via such specific channels. GBI retains
the rights to license the use of Virastatin(TM) in over-the-counter
pharmaceutical products and for the possible development of ethical drugs. The
global marketplace for antiviral products is extremely large and compared to
other categories of pharmaceuticals, has limited competition. A March 2003
Reuters report states that, "The global antivirals market is forecast to grow
from $8.7 billion in 2001 to $14 billion in 2007, largely due to the high
incidence of viral infections and the inadequate efficacy of the drugs currently
available". The family of human herpes viruses, currently with nine members,
presents a good example of the extremely large potential marketplace for
antiviral products. This family of contagious viruses infects almost everyone on
the planet regardless of their geographic location. The best available data
suggests that herpes simplex-1 (the cold sore virus) infects around 60% of the
population; herpes simplex-2 (the genital herpes virus) infects around 26% of
the population; varicella (the chicken pox and shingles virus) infects around
90% of the population; Epstein-Barr virus (the mononucleosis virus) infects
around 60% of the population; cyomegalovirus infects around 95% of the
population; and human herpes viruses 6 and 7 infect between 75 and 98% of the
population. These viruses, in addition to causing classical herpes virus
diseases, are now being linked as a contributing factor in the development of at
least three diseases, which are the leading causes of death in developed
nations. These diseases are heart disease, cancer and Alzheimer's disease.
Herpes virus infections have also been recently linked with development of other
serious conditions such as, hypertension, atherosclerosis, multiple sclerosis,
Bell's palsy, trigeminal neuralgia, Hodgkin's disease, lymphoma and leukemia.
Many medical professionals have suggested exploring the expanded use of
antiviral agents as a treatment for many of these diseases. GBI's flagship
antiviral product, Virastatin(TM), has demonstrated exceptional efficacy in
products targeted against the herpes family of viruses. Additionally, several
other very important viral diseases are the subjects of pending patent
applications by GBI. These new viral disease indications will expand even
further the impact that GBI's antiviral products, such as Virastatin(TM), will
have on global health.

To produce Virastatin(TM), Larrea plant material is harvested from native stands
of the plant growing in pristine areas of the Sonoran Desert. The
environmentally friendly harvesting methods designed exclusively for GBI, do not
kill or permanently damage the Larrea plants thereby providing a sustainable
natural resource. To keep initial capital investment to a minimum, GBI currently
outsources the manufacturing of Virastatin(TM) resin. However, the Company may
begin insourcing production of Virastatin(TM) and other Larrea-based products at
GBI-owned and operated facilities in the near future. These manufacturing
advances would decrease the cost of goods sold, thereby increasing the Company's
profitability. GBI has also employed the resources of Four Square Group
(Phoenix, Arizona), a governmental and public affairs firm, working on behalf of
GBI to secure Larrea harvesting rights on large tracts of government-owned lands
in the Southwest U.S.


                                       3
<PAGE>

COMPANY BUSINESS MODEL

Since the acquisition of GBI, the Company's business model focuses on
production, marketing and selling of its products, Virastatin(TM) proprietary
resin, Shegoi(TM) and Virox nutriceutical and cosmeceutical products.

Global Botanics currently utilizes a laboratory facility located at the Maricopa
Agricultural Center, University of Arizona. With the complete establishment of
this lab they will have the capacity to extract and process enough plant
material into finished resin to produce (in house) enough resin for up to 15,000
bottles per day of the dietary supplement.

In addition, and as a back up, the Company utilizes the services of Pioneer
Laboratories (Tonopah, AZ), to extract and process the plant material, using
proprietary methods. Pioneer has current resin production capacity to satisfy
the needs of approximately 666,000 finished dietary supplement bottles per month
(60 capsules/bottle).

The Products

GBI specializes in the research and development of products from the desert
shrub, Larrea tridentata. The Company's flagship product is a proprietary
extract from the plant, which is marketed under the tradename Virastatin. The
extract and products based on the extract are protected by four (4) US patents
(#6,039,955; #6,004,559; #5,945,106; #5,837,252). The patented extract functions
as a natural remedy for herpes-related disorders and inflammatory conditions.

GBI's major product categories include nutriceutical, cosmeceutical and
over-the-counter pharmaceutical products based on the Virastatin(TM) extract.
The product line, which consists of a dietary supplement product, a topical
spray and topical lotion product have been obtained through a licensing
agreement, by LarreaRx, Inc., GBI's primary customer.

LarreaRx, Inc. distributes the products via two different distribution channels.
Products sold under the Virox tradename are distributed and marketed through
retail channels and are available throughout Canada and the US in numerous
pharmacies and health food retail outlets. The same product line is also
marketed under the brandname and label, Shegoi, and is distributed and marketed
through direct marketing channels.

Larrea BioSciences Corporation maintains a website at www.labsci.com. LarreaRx,
Inc. maintains websites at www.virox.ca and www.shegoi.com

STATUS OF NEW PRODUCTS AND SERVICES

Larrea Biosciences Corporation is engaged in the industrial field of applied
biosciences research and development. The Company plans to become the world
leader in the industrialization and commercialization of Larrea for a wide range
of health and consumer products. The Company anticipates the introduction of
several different grades of Virastatin resin extract over the next fiscal year.
The goal of this strategy will be to lower production costs, while at the same
time, expanding the target market for the Company. Numerous products in the
consumer health products category, anti-aging products, health and beauty
products, dental products and veterinary products will be introduced.

Growth through Establishing Partners Network

Larrea Biosciences has announced the intended acquisition of LarreaRx, Inc., its
major licensee. This acquisition will result in the envelopment of LarreaRx's
operations under the Larrea Biosciences umbrella, such that Larrea Biosciences
will enjoy the substantial revenues and benefits of the retail distribution and
direct marketing efforts of the Licensee.

Strategic Alliances

Larrea Biosciences will provide opportunities for additional licensing
relationships with other companies in the nutriceutical, cosmeceutical,
pharmaceutical and network marketing industries. Specifically, the proprietary
extract will continue to be manufactured and produced under the control of GBI
and GBI will aid any new licensees with product development as necessary.

Larrea Biosciences' strategic sub-licensing agreements will accelerate
distribution and could result in immediate revenue from licensing fees, and
ongoing revenues from product sales, royalty or resin purchases. Sub-licensees
will cultivate and develop network marketing, direct sales endeavors and retail
marketing in those countries with proven industry track records.

MARKETING AND SELLING

The Marketing Program

While affiliations and partnering result in potential growth for the Company,
marketing and selling remain essential to building Company revenue. The
objective of the Company's marketing program is to create and sustain preference
and loyalty for Larrea Biosciences and GBI, as a leading providers of
proprietary Virastatin resin extract.

The major marketing functions for the retail sector are performed by the major
marketing partner of GBI, LarreaRx Inc. This marketing partner has the overall
responsibility for communications, advertising, public relations and the
establishment of the retail and product information websites. Virox products are
distributed throughout the US through Tree of Life, United Natural Foods
Incorporated, Select Nutrition and selected Whole Foods outlets. Puresource Inc.
and Asenda Pharmaceuticals represent the products in Canada. Consumers can
purchase Virox through Whole Foods, Akin's, Chamberlain's, Vitamin Cottage,
selected Vitamin World and other health food retailers in the US. Safeway,
London Drugs, Save-On Foods, Whole Foods, Capers, Overwaitea, Thrifty Foods and
other health food stores retail the products in Canada.


                                       4
<PAGE>

Shegoi products are available through a network distribution channel, which
currently consists of 2,700 distributors. The initial launch of the Shegoi
products occurred in October, 2003. Additional network and direct marketing
outlets will be secured this year in order to increase the powerful reach that
this type of marketing campaign can deliver.

The Markets

Larrea Biosciences is targeting the global antiviral and dermatology markets
with it's Virastatin(TM)-based products. The global antiviral market is forecast
to grow to $14 billion by 2007, while the dermatology market is valued at $15
billion. With a major R&D focus on herpes treatments, a market valued at
approximately $1.8 billion will be readily available over the next four years.
There are over 100 million herpes virus sufferers in North America alone.

Virastatin(TM)-based products have demonstrated excellent results in treating
conditions caused by the herpes class of viruses including cold sores, genital
herpes and shingles; inflammatory conditions, including joint disorders,
sinusitis, gastrointestinal disorders, psoriasis; and various microbial and
fungal conditions. Currently, GBI has licensed the use of its proprietary
ingredient to LarreaRx, Inc. for incorporation into a line of nutriceutical, and
cosmeceutical products for sale and distribution through retail and direct
marketing channels. LarreaRx provides its products primarily to customers for
personal use and also to healthcare practitioners.

CURRENT MARKET OPPORTUNITIES INCLUDES:

o     HEALTHY INDIVIDUALS

      general health, illness prevention via antioxidant activity

o     AGING INDIVIDUALS

      anti-aging, health and beauty needs

o     ELDERLY INDIVIDUALS

      shingles, post-herpetic neuralgia & other age-related diseases induced by
      viral infection or inflammatory problems such as arthritis and psoriasis,
      etc.

o     FEMALE INDIVIDUALS

      cosmetics, health and beauty needs

o     SEXUALLY ACTIVE INDIVIDUALS

      prevention and/or health maintenance of STD's (herpes virus, papilloma
      virus)

o     IMMUNE COMPROMISED INDIVIDUALS (SUFFERING FROM OPPORTUNISTIC INFECTIONS)

      AID's infected individuals with Kaposi's sarcoma, genital herpes,
      cytomegalovirus, etc., transplant patients, etc.



MARKET EXPANSION OPPORTUNITIES INCLUDE:

o     PREVENTION/MAINTENANCE OF AGE-RELATED DISEASES

      (cancer, heart disease, liver disease, arthritis)

o     PREVENTION/MAINTENANCE OF NEURODEGENERATIVE DISEASE

      (multiple sclerosis, Alzheimers)

o     PREVENTION/TREATMENT OF INFECTION

      (viral infections, bacterial infections, fungal infections)

o     DENTAL APPLICATIONS

      (canker sores, gingivitis, etc.)

o     SPORTS INJURY APPLICATIONS

      (joint inflammation)

o     COSMETICS/COSMETIC SURGERY APPLICATIONS

      (scar reduction, anti-wrinkle, etc.)

o     VETERINARY APPLICATIONS

Manufacturing and production activities for the proprietary extract take place
in Phoenix, Arizona, which has the most abundant stands of the Larrea tridentata
plant. Thus far, LarreaRx, Inc. has been the major licensee of GBI's proprietary
extract. Thus, all of the revenues since the GBI's inception have been generated
through sales of Virastatin(TM) resin to LarreaRx. GBI itself intends to enter
additional licensing agreements within the next several months to increase the
revenue stream. Additionally, LarreaRx has also begun negotiations for expanded
product distribution and partnerships through their retail and network marketing
channels, which would translate into increased demand for GBI's proprietary
resin extract.

FISCAL YEAR 2004 PERFORMANCE OVERVIEW

Prior to the acquisition of GBI, there were no operations in Larrea Biosciences.
Since the acquisition of GBI, the revenue potential of Larrea Biosciences has
increased tremendously.


                                       5
<PAGE>

EMPLOYEES

As of April 30, 2004, Larrea Biosciences had no employees.

COMPETITION

No toxicity has been recognized from any Company sponsored in vitro and in vivo
animal studies, independent in vitro and in vivo animal studies,
Company-sponsored non-controlled human clinical studies or in non-controlled
human clinical studies conducted by independent researchers utilizing
Virastatin(TM). Likewise, no consumer use reports have indicated toxicity or
adverse effects from the use of or Virastatin(TM) in topical or oral form.

The products have been in test market for over six years with great success.

While there are other Larrea-based products on the market, these products do not
produce the same medicinal results as Virastatin(TM). Also, their performance is
limited, because the products are not readily absorbed into the digestive tract.
More important is the fact that toxins capable of inducing liver damage have
been associated with other larrea-based products. The proprietary processing
methods of Virastatin(TM) provide the non-toxic quality to the Company's extract
and products. Thus, key is the fact that each of the Virastatin(TM)-based
products are formulated to achieve the highest degree of potency without the
toxicity risks found in other Larrea-based products.

Additionally, no other patents award the right to use the current proprietary
extract or any other extract of larrea for the purpose of treating herpes and
inflammatory conditions. The Company is in the process of expanding its current
patent and product portfolio to encompass greater utility of the plant.

CUSTOMERS

Larrea Biosciences current customer base includes LarreaRx, Inc. As of April 30,
2004, and prior to the consummation of the GBI acquisition, the Company had no
customers and thus no revenue.

OPERATIONS

The Company's headquarters are in Vancouver, British Columbia. One hundred
percent of the proprietary resin is harvested in Arizona. Nearly 45% of
LarreaRx's production of final product occurs in Canada and 55% of the final
products are manufactured in the United States.

ORGANIZATION

Larrea Biosciences Corporation (formerly Sonic Media Corporation) was organized
as a Nevada corporation. The Company amended its Articles of Incorporation on
June 1, 2004 to change its name to Larrea BioSciences Corporation.

Intellectual Property

The Company, through GBI owns U.S. Patents 5,837,252; 5,945,106; 6,004,559 and
6,039,955. These patents relate to the production and use of proprietary
extracts from the North American plant species, Larrea tridentata. The current
patented technology broadly covers extraction and purification technologies as
well as utility of extracts as antiviral, anti-inflammatory, antimicrobial and
antioxidant agents. Specific claims allowed in the issued patents include: a
method of treating herpes lesions and herpes viruses in humans using an
effective amount of an extract of Larrea tridentata; a method of treating herpes
viruses and symptomatic herpes virus lesions of the group: herpes simplex 1
(cold sores), herpes simplex 2 (genital herpes), varicella-zoster virus
(chickenpox and shingles), human herpes virus 4 (Epstein-Barr virus,
mononucleosis), human herpes virus 5 (cytomegalovirus), human herpes viruses 6
and 7 (roseoloviruses), and herpes virus 8 (Kaposi's sarcoma); stimulation of
human immune system function; a herpes treatment agent comprising a formulation
of Larrea tridentata; and an agent for treatment of inflammation and
inflammatory disease comprising a formulation of Larrea tridentata. These
patents, which issued between 1998 and 2000, remain as an effective barrier to
competition for twenty years from the date filed. In addition to the existing
patents, GBI will aggressively prosecute pending patent applications to secure
final issuance of multiple U.S. and international patents, which expand on the
already patented technologies. GBI will actively pursue new licensees for its
patented technologies both domestically and overseas.

The Company relies upon a combination of nondisclosure and other contractual
arrangements, as well as common law trade secret, copyright and trademark laws
to further protect its proprietary rights. The Company enters into
confidentiality agreements with its consultants and clients and limits access to
and distribution of its proprietary information. The product names Virastatin
and Shegoi are trademarked in the U.S.

GOVERNMENTAL APPROVAL AND REGULATION

Like all companies, including those with multinational operations, we are
subject to the laws of the countries in which the Company maintains subsidiaries
and conducts operations. Additionally, there are regulatory guidelines that are
to be followed when selling natural plant extracts, dietary supplement and
cosmetic products. The specific regulations and extent of the regulations vary
from country to country. Larrea Biosciences relies on the advice of regulatory
affairs consultants and legal council to stay within any guidelines and
regulations imposed by each government on our industry.


                                       6
<PAGE>


ITEM 2 - PROPERTIES

COMPANY FACILITIES

The Company's current facilities are located at 55-400 Water Street, Vancouver,
British Columbia V6B1A1.

ITEM 3 - LEGAL PROCEEDINGS

No law suits are currently threatened or filed against or by Larrea Biosciences
or GBI.

ITEM 4 - SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

On May 3, 2004, LBC filed a definitive proxy statement for an action by written
consent of the stockholders to vote on an amendment of the Company's Articles of
Incorporation to effect a name change from Sonic Media Corporation to Larrea
BioSciences Corporation. As of the record date of April 13, 2004, there were
16,230,760 shares issued and outstanding. 8,300,000 (51.14%) voted in favor of
the name change. Pursuant to the above-mentioned proxy statement, the Company
implemented the name change by filing the amended articles of incorporation with
the Nevada Secretary of state on May31, 2004. On June 5, 2004, the Company's
symbol was changed from SMED to LRRA.


                                     PART II

ITEM 5 - MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS;
RECENT SALES OF UNREGISTERED SECURITIES

(a) MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

MARKET INFORMATION - Common stock of Larrea BioSciences Corporation is traded on
the NASD's Over the Counter Bulletin Board under the symbol "LRRA."

The table shows the high and low bid and ask of the Company's common stock as
reported for each quarter during the last two fiscal years:


                                            2003-2004            2002-2003

    Fiscal
    Quarter                              High       Low        High       Low
    -------                              ----       ---        -----      ---

1st (ended July 31)                      0.0        0.00       0.00       0.00
2nd  (ended October 31)                  0.25       0.25       0.00       0.00
3rd (ended January 31)                   1.63       1.53       0.00       0.00
4th (ended April 30)                     1.20       1.20       0.00       0.00


RECORD HOLDERS - As of July 25, 2004, the number of holders of record of the
Company's common stock was eight (8). As of July 25, 2004, there were 16,230,760
shares of common stock issued and outstanding.

DIVIDENDS - The Company has not paid dividends on its Common Stock in the past
and does not anticipate doing so in the foreseeable future. The Company
currently intends to retain future earnings, if any, to fund the development and
growth of its business.

SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS.

As of April 30, 2004, the Company had no equity compensation plans in place.

(b) RECENT SALES OF UNREGISTERED SECURITIES

On March 26, 2004, the Company entered into an agreement with the shareholders
of GBI whereby the Company acquired all of the issued and outstanding shares of
GBI in exchange for 3,500,000 shares of restricted common stock of the Company.
As all the shareholders of GBI were non-U.S. residents, the shares were issued
in reliance on an exemption from registration available under Regulation S of
the Securities Act of 1933. The shares, due to the shareholders of GBI from the
Company, were not issued until August 2004.

ITEM 6 - MANAGEMENT'S DISCUSSION AND ANALYSIS AND PLAN OF OPERATIONS

At April 30, 2004, the Company had no operations. With the acquisition of GBI,
the Company's entire management and global marketing and sales team have set
clear goals and objectives to expand distribution and marketing of the
Virastatin(TM) resin on a global basis. As well, the Company will continue to
engage in research and new product development.

Going forward, the management has set new goals to achieve over the next two
quarters.

      o     The acquisition of LarreaRx, Inc., GBI's primary licensee

      o     Expanded distribution of Virastatin(TM)to new licensees for private
            label use

      o     Expanded distribution of Virastatin-based products for license to
            nutriceutical, cosmeceutical, pharmacueitcal and veterinary markets

      o     Broadening of Intellectual property portfolio for increased security
            and protection of claims, utility and processing methods

      o     Reducing cost of production via in-house manufacturing and/or
            increased volume production

      o     Research and Development - clinical studies, product development,
            etc.


                                       7
<PAGE>


CHANGE IN MANAGEMENT AND BOARD OF DIRECTORS

During the fiscal year 2003-2004, the directors of SMED appointed David T.
Kalenuik and Robert T. Sinnott as members of the board of directors filling
available vacancies. After the resignation of Messieurs Finkelstein and Jarva,
Mr. Kalenuik and Mr. Sinnott constitute the sole members of the board of
directors. Mr. Kalenuik also acts as CEO of the Company. Mr. Sinnott acts as the
Treasurer and Secretary.

Committees

The Company is in the process of forming an Audit, Compensation and Nominating
and Corporate Governance Committee. Currently Mr. Kalenuik and Mr. Sinnott are
acting as members of these committees.

RESULTS OF OPERATIONS

THE YEAR ENDED APRIL 30, 2004 COMPARED TO THE YEAR ENDED APRIL 30, 2003

The Company incurred a net loss of $112,733 as compared to $7,333 for the year
ended April 30, 2003 an increase of $105,400. The increased loss is directly
attributable to an increase in management and consulting fees and professional
fees.

Management and consulting fees increased by $82,328 for the year ended April 30,
2004. The increase is due to an increase in the number of outside consultants
utilized during the year.

Professional fees, which include legal and audit fees, increased by $21,236 for
the year ended April 30, 2004. Legal and accounting expenses relate to financial
and regulatory requirements.

Loss per share was $0.01 in 2004 compared to $0.00 in 2003 after giving effect
to a 6.5 to 1 stock split. The increasing loss per share is due to the increase
in the loss during the 2004 fiscal year. The weighted average number of shares
outstanding for the years ending April 30, 2004 and 2003 was 16,230,760 after
giving effect to a 6.5 to 1 stock split.

Stockholder deficiency as at April 30, 2004 was $19,862 compared to stockholder
equity of $92,871 as at April 30, 2003.

Going Concern Qualification

The Company's independent auditors have included an explanatory paragraph in
their report on the April 30, 2004 consolidated financial statements discussing
issues which raise substantial doubt about the Company's ability to continue as
a "going concern." The going concern qualification is attributable to recurring
losses. For the year ended April 30, 2004, the Company continued to experience a
negative cash flow from operations, and projects that it will need certain
additional capital to enable it to continue operations at its current level
beyond the near term. The Company believes it can raise additional funds though
equity or debt financing.

Liquidity And Capital Resources

As of April 30, 2004 the Company's working capital deficiency (current assets
less current liabilities) totaled $19,862 compared to working capital of $92,871
as of April 30, 2003. Cash flows used in operating activities totaled $99,307
for the year ended April 30, 2004 compared to $759 for the year ended April 30,
2003. As of April 30, 2004, the Company had cash on hand of $138 and a working
capital deficiency of $19,682. In the opinion of management, cash on hand is not
sufficient to meet the Company's current needs.

Dividends and Redemption

It has been the Company's policy to invest earnings in the growth of the Company
rather than distribute earnings as dividends. This policy, under which dividends
have not been paid since the Company's inception and is expected to continue,
but is subject to regular review by the Board of Directors.

Forward-Looking Statements

All statements contained in this annual report, or in any document filed by the
Company with the Securities and Exchange Commission, or in any press release or
other written or oral communication by or on behalf of the Company, that do not
directly and exclusively relate to historical facts constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements represent the Company's expectations and beliefs, and
no assurance can be given that the results described in such statements will be
achieved.

These statements are subject to risks, uncertainties and other factors, many of
which are outside of the Company's control that could cause actual results to
differ materially from the results described in such statements. These Factors
include, without limitation, the following: (i) competitive pressures; (ii) the
Company's ability to consummate strategic acquisitions and alliances; (iii) the
Company's ability to attract and retain key personnel; (iii) the Company's
ability to continue to develop and expand its product offerings to address
emerging business demands and technological trends; (iv) changes in the
financial condition of the Company's customers; (v) the future profitability of
the Company's customer contracts, and (vi) general economic conditions and
fluctuations in currency exchange rates in countries in which we do business.


                                       8
<PAGE>


ITEM 7. FINANCIAL STATEMENTS

The Financial Statements that constitute Item 7 are included at the end of this
report on page F-1.

ITEM 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE

On June 21, 2004, the Company changed accountants beginning with the audit of
the financial statements for the fiscal year ended April 30, 2004, from Anderson
Accounting to LDMB Advisors, Inc. ("LDMB"). The Board of Directors of Larrea
Biosciences approved the change in auditors at a special meeting of the Board of
Directors.

The report of Anderson  on the Company's financial statements for the fiscal
year ended April 30, 2003 and LDMB's report on the Company's financial
statements for the fiscal year ended April 30, 2004, did not contain an adverse
opinion or disclaimer of opinion, and was not qualified or modified as to
uncertainty, audit scope, or accounting principles, except for a going concern
uncertainty.

In connection with the audit of the Company's financial statements for the
fiscal years ended April 30, 2003, there were no disagreements, disputes, or
differences of opinion with Anderson on any matters of accounting principles or
practices, financial statement disclosure, or auditing scope and procedures,
which, if not resolved to the satisfaction of Anderson would have caused
Anderson to make reference to the matter in its report.

In connection with the audit of the Company's financial statements for the
fiscal year ended April 30, 2004 there were no disagreements, disputes, or
differences of opinion with LDMB on any matters of accounting principles or
practices, financial statement disclosure, or auditing scope and procedures,
which, if not resolved to the satisfaction of LDMB would have caused LDMB to
make reference to the matter in its report.

ITEM 8A. CONTROLS AND PROCEDURES

Management, under the supervision and with the participation of the chief
executive officer and chief financial officer, conducted an evaluation of the
disclosure controls and procedures as of the effective date of this Annual
Report on Form 10-KSB. Based on their evaluation, the chief executive officer
and chief financial officer have concluded that as of the evaluation date, the
disclosure controls and procedures are effective to ensure that all material
information required to be filed in this Annual Report on Form 10-KSB has been
made known to them.


Other than as described above, there have been no changes, including corrective
actions with regard to deficiencies or weaknesses in the Company's internal
controls or in other factors that could significantly affect these controls
subsequent to the evaluation date set forth above.

                                    PART III

ITEM 9. DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS; COMPLIANCE
WITH SECTION 16(A) OF THE EXCHANGE ACT

Section 16(a) of the Securities Exchange Act of 1934, as amended, requires that
the Company's directors and executive officers and persons owning more than 10%
of the outstanding Common Stock, file reports of ownership and changes in
ownership with the Securities and Exchange Commission ("SEC"). Executive
officers, directors and beneficial owners of more than 10% of the Company's
Common Stock are required by SEC regulation to furnish the Company with copies
of all Section 16(a) forms they file.

Based solely on copies of such forms furnished as provided above, or written
representations that no Forms 5 were required, the Company believes that during
the fiscal year ended April 30, 2004, all Section 16(a) filing requirements
applicable to its executive officers, directors and beneficial owners of more
than 10% of its Common Stock were complied with, except as follows: Mr. David
Kalenuik did not timely file a Form 5; however, the form 5 was filed on August
3, 2004. Mr. Robert Sinnott did not timely file a Form 5; however, the form was
filed on August 3, 2004.


                                       9
<PAGE>


DIRECTORS AND EXECUTIVE OFFICERS

The following table sets forth the names and ages of the current directors and
executive officers of the Company, the principal offices and positions with the
Company held by each person and the date such person became a director or
executive officer of the Company. The Board of Directors elects the executive
officers of the Company annually. Each year the stockholders elect the Board of
Directors. The executive officers serve terms of one year or until their death,
resignation or removal by the Board of Directors. In addition, there was no
arrangement or understanding between any executive officer and any other person
pursuant to which any person was selected as an executive officer.

The directors and executive officers of the Company are as follows:

<TABLE>
<CAPTION>
----------------------- -------------------------- ------- -------------------------------------- -----------------
Name                    Year First Elected As an   Age     Position
                        Officer                            Held with                              Family
                        Or Director                        the Registrant                         Relationship
----------------------- -------------------------- ------- -------------------------------------- -----------------
<S>                     <C>                        <C>     <C>                                    <C>
David Kalenuik          2004                       46      CEO; Director                          None
----------------------- -------------------------- ------- -------------------------------------- -----------------
Robert Sinnott          2004                       39      Treasurer, Secretary; Director         None
----------------------- -------------------------- ------- -------------------------------------- -----------------
</TABLE>

Business Experience of Officers and Directors:

DAVID KALENUIK has been a Director of the Company since 2004. Mr. Kalenuik is
currently the Chief Executive Officer of the Company. Mr. Kalenuik is a
businessman, consultant and marketing entrepreneur. He has been involved in the
Direct Marketing/Multi-Level Marketing and Tele-Marketing industry for over 25
years. He has consulted to and supplied products to a number of Network
Marketing companies. He was also the founder and President of a Network
Marketing company, FIM, where he grew an Independent Distributor base of over
65,000 people within a calendar year. Additionally, he was Co-founder and
President of Mitropolis Solutions Inc, an Investment Banking firm, which funded
over $6,000,000 USD in private placement funding to private companies during the
late 1990's. David has owned and successfully operated over ten companies within
Canada and the United States and has been a director and officer in publicly
traded companies.

ROBERT SINNOTT has been a Director of the Company since 2004. Mr. Sinnott is
currently the Chief Financial Officer and Secretary of the Company. Dr. Sinnott
is Chief Executive Officer and Director of Larreacorp and is a businessman,
researcher and consultant. He holds a Doctor of Philosophy from Arizona State
University specializing in plant genetic engineering and agricultural
biotechnology. Dr. Sinnott was the founder of Gaiaventures, Ltd., the
predecessor of Larreacorp, based in Chandler, Arizona. Gaiaventures provided
technology assessment and product development for contract clients in the
biotechnology, pharmaceuticals, and functional food industries. Past clients
include start-up companies and Fortune 500 companies such as Mars Corporation
and IMPRA, now a subsidiary of Bard. Dr. Sinnott has taught biotechnology and
biotech-based business courses at the college level at several institutions.

ITEM 10-EXECUTIVE COMPENSATION

SUMMARY COMPENSATION TABLE AND OPTIONS

The Summary Compensation Table shows certain compensation information for
services rendered in all capacities during each of the last three fiscal years
by the executive officers of the Company who received compensation of or in
excess of $100,000 during the fiscal year ended April 30, 2004. The following
information for the officers includes the dollar value of base salaries, bonus
awards, the number of stock options granted and certain other compensation, if
any, whether paid or deferred.


                           SUMMARY COMPENSATION TABLE
---------------------------------- --------------- -----------------------------
                                                     Annual Compensation(1)(2)
---------------------------------- --------------- -----------------------------
                                    Fiscal Year
Name and Principal Position           Ended          Salary          Bonus
---------------------------------- --------------- ------------ ----------------

David Kalenuik, Chief Executive    2004            $ 0          -0-
Officer Director
                                   2003            n/a          -0-

                                   2002            n/a          -0-

---------------------------------- --------------- ------------ ----------------
Robert Sinnott,  Treasurer,        2004            $0           -0-
Secretary and Director
                                   2003            n/a          -0-

                                   2002            n/a          -0-
---------------------------------- --------------- ------------ ----------------


(1) No officers received or will receive any bonus or other annual compensation,
nor any benefits other than those available to all other employees that are
required to be disclosed.

(2) No officers received or will receive any long-term incentive plan (LTIP)
payouts or other payouts during fiscal 2003.

(3) No officers received any options or other forms of compensation in the 3
most recent fiscal years.


                                       10
<PAGE>

COMPENSATION OF DIRECTORS

Directors of the Company do not receive cash compensation for attendance at
board meetings but are entitled to reimbursement of their reasonable expenses
incurred in attending Directors' Meetings.

ITEM 11- SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information regarding the beneficial
ownership of the Company's Common Stock, its only class of outstanding voting
securities as of July 15, 2004, by (i) each person who is known to the Company
to own beneficially more than 5% of the outstanding Common Stock with the
address of each such person, (ii) each of the Company's present directors and
officers, and (iii) all officers and directors as a group:


                                                                    Percentage
Name and                                   Number of               Beneficially
Address                                  Shares(1)(2)                 owned
-------                                  ------------              ------------

David Kalenuik (3)                         4,150,000                  25.56%
Robert Sinnott (3)                         4,150,000                  25.56%

All officers and directors
as a group (two persons)                   8,300,000                  51.12%

(1) Except as otherwise indicated, the Company believes that the beneficial
owners of Common Stock listed below, based on information furnished by such
owners, have sole investment and voting power with respect to such shares,
subject to community property laws where applicable. Beneficial ownership is
determined in accordance with the rules of the Securities and Exchange
Commission and generally includes voting or investment power with respect to
securities.

(2) Beneficial ownership is determined in accordance with the rules of the
Commission and generally includes voting or investment power with respect to
securities. Shares of Common Stock relating to options currently exercisable or
exercisable within 60 days of July 15, 2004 are deemed outstanding for computing
the percentage of the person holding such securities but are not deemed
outstanding for computing the percentage of any other person. Except as
indicated by footnote, and subject to community property laws where applicable,
the persons named in the table above have sole voting and investment power with
respect to all shares shown as beneficially owned by them.

(3) Address c/o David Kalenuik 400-55 Water Street, Vancouver, British Columbia
V6B 1A1, Canada.

ITEM 12-CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.

The Company's management believes that the terms of these transactions are no
less favorable to the Company than would have been obtained from an unaffiliated
third party in similar transactions. All future transactions with affiliates
will be on terms no less favorable than could be obtained from unaffiliated
third parties, and will be approved by a majority of the disinterested
directors.


                                     PART IV

ITEM 13 - EXHIBITS AND REPORTS ON FORM 8-K

(a) Exhibits

         21.1     A list of all subsidiaries of the Company *
         31.1     Section 302 Certification *
         31.2     Section 302 Certification *
         32.1     Section 906 Certification *
         32.2     Section 906 Certification *

*     Filed herewith.

(b) Reports on Form 8-K

      On February 3, 2004, the Company filed a current report on form 8-K
announcing the change of auditors from Sellers and Anderson LLC to Madsen &
Associates. The change in auditors occurred because of a move of the auditing
partner to a new firm. There was no disagreement with the Company's previous
auditors.

      On February 11, 2004, the Company filed a current report on form 8-K
announcing its intention to acquire Global Botanics, Inc.


                                       11
<PAGE>

      On March 15, 2004, the Company filed a current report on form 8-K
announcing a change in control whereby the controlling shareholders of the
Company sold 9,750,000 shares of the Company's common stock to various
shareholders including David Kalenuik and Robert Sinnott in exchange for a total
consideration of $100,000. This current report also announced the resignation of
Kenneth Finkelstein and Robert Jarva and the appointment of David T. Kalenuik
and Robert Sinnott, Ph.D. to act as directors and officers of the Company until
its next annual meeting.

      On March 16, 2004, the Company filed a current report announcing the
replacement of its attorney Kenneth Finkelstein with Patti L. W. McGlasson, a
Professional law corporation.

      On April 20, 2004, the Company filed a current report announcing the
acquisition of all of the shares of common stock of Global Botanics, Inc. in
exchange for 3,500,000 shares of common stock of the Company.


                                   SIGNATURES


In accordance with Section 13 or 15 (d) of the Exchange Act, the Registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.


                                           LARREA BIOSCIENCES COPORATION


Date:        August 30, 2004               BY: /S/ DAVID KALENUIK
                                           ----------------------
                                           David Kalenuik, Acting CEO


Date:        August 30, 2004               BY: /S/ ROBERT SINNOTT
                                           ----------------------
                                           Robert Sinnott, Acting CFO


In accordance with the Exchange Act, this report has been signed below by the
following persons on behalf of the Registrant and in the capacities and on the
dates indicated.


Date:        August 30, 2004               BY: /S/ DAVID KALENUIK
                                           ----------------------
                                           David Kalenuik, Director


Date:        August 30, 2004               BY: /S/ ROBERT SINNOTT
                                           ----------------------
                                           Robert Sinnott, Director


                                       12

<PAGE>




                         LARREA BIOSCIENCES CORPORATION
                          (FORMERLY SONIC MEDIA CORP.)
                          (A DEVELOPMENT STAGE COMPANY)
                              FINANCIAL STATEMENTS

                                 APRIL 30, 2004


<PAGE>


LARREA BIOSCIENCES CORPORATION


CONTENTS

APRIL 30, 2004



                                                                           PAGE



REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM                    F-1


FINANCIAL STATEMENTS
     Balance Sheets                                                        F-2
     Statements of Operations                                              F-3
     Statements of Stockholders' Equity                                    F-4
     Statements of Cash Flows                                              F-5
     Notes to the Financial Statements                                     F-6


<PAGE>

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


To the Stockholders of:
Larrea Biosciences Corporation (formerly Sonic Media Corp.)

We  have  audited  the  balance  sheet  of  Larrea  Biosciences  Corporation  (a
development  stage  company)  as  at  April  30,  2004  and  the  statements  of
operations,  stockholders'  equity and cash flows for the year then ended. These
financial  statements are the  responsibility of the Company's  management.  Our
responsibility  is to express an opinion on these financial  statements based on
our audit.  The financial  statements as of April 30, 2003 and for the year then
ended were audited by other auditors whose report dated June 20, 2003, expressed
an  unqualified  opinion  on these  statements.  The  cumulative  statements  of
operations,  stockholders' equity and cash flows for the period from May 1, 2002
(inception)  to April 30, 2003  include  amounts for the period from May 1, 2002
(inception)  to April 30,  2003,  which  were  audited by other  auditors  whose
reports have been furnished to us, and in our opinion,  insofar as it relates to
the amounts  included for the period May 1, 2002 through April 30, 2003 is based
solely on the reports of other auditors.

We  conducted  our audit in  accordance  with  Standards  of the Public  Company
Accounting Oversight Board (United States). Those standards require that we plan
and  perform  an audit to obtain  reasonable  assurance  whether  the  financial
statements are free of material misstatement.  An audit includes examining, on a
test basis,  evidence  supporting  the amounts and  disclosures in the financial
statements.  An audit also includes assessing the accounting principles used and
significant  estimates  made by  management,  as well as evaluating  the overall
financial  statement  presentation.   We  believe  that  our  audit  provides  a
reasonable basis for our opinion.

In our  opinion,  based on our audits and the  report of other  auditors,  these
financial  statements  present fairly, in all material  respects,  the financial
position of the  Company as at April 30, 2004 and the results of its  operations
and cash flows for the year then ended and cumulative for the period from May 1,
2002  (inception)  to April 30, 2004 in conformity  with  accounting  principles
generally accepted in the United States of America.

The  accompanying  financial  statements  have been  prepared  assuming that the
Company  will  continue  as a  going  concern.  As  discussed  in  Note 1 to the
financial statements,  the Company has suffered recurring losses from operations
and negative cash flows from operations that raise  substantial  doubt about its
ability to continue as a going  concern.  Management's  plans in regard to these
matters are also  described in Note 1. The  financial  statements do not include
any adjustments that might result from the outcome of this uncertainty.

/s/ LDMB Advisors Inc.

Chartered Accountants
Langley, British Columbia, Canada
August 6, 2004

                                      F-1
<PAGE>

LARREA BIOSCIENCES CORPORATION
The accompanying notes are an integral part of these financial statements.

(FORMERLY SONIC MEDIA CORP.)
(A DEVELOPMENT STAGE COMPANY)

BALANCE SHEETS

<TABLE>
<CAPTION>
--------------------------------------------------------------------------------------------
AS AT APRIL 30,                                                 2004               2003
--------------------------------------------------------------------------------------------
<S>                                                          <C>               <C>
ASSETS

CURRENT
    Cash                                                     $      138        $    99,445
============================================================================================

LIABILITIES

CURRENT
    Accounts payable and accrued liabilities                 $   20,000        $     6,574
--------------------------------------------------------------------------------------------

STOCKHOLDERS' EQUITY

    Common stock, $.0001 par value
        Authorized:  100,000,000 shares
        Issued:  2004 - 16,230,760; 2003 - 4,997,040              1,623                500
    Additional paid-in capital                                   98,581             99,704
    Deficit accumulated during the development stage           (120,066)            (7,333)

--------------------------------------------------------------------------------------------
Total stockholders' equity                                      (19,862)            92,871

--------------------------------------------------------------------------------------------
                                                             $      138        $    99,445
============================================================================================
</TABLE>

COMMITMENTS (Note 6)


APPROVED BY THE DIRECTORS:

/s/ David Kalenuik
--------------------------
Director

/s/ Robert Sinott
--------------------------
Director


The accompanying notes are an integral part of these financial statements.

                                       F-2

<PAGE>

LARREA BIOSCIENCES CORPORATION

(FORMERLY SONIC MEDIA CORP.)
(A DEVELOPMENT STAGE COMPANY)

STATEMENTS OF OPERATIONS


<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------
                                                                                     PERIOD FROM
                                                                               MAY 1, 2002 (INCEPTION)
                                                                                    TO APRIL 30,
FOR THE YEARS ENDED APRIL 30,                          2004           2003              2004
------------------------------------------------------------------------------------------------------
<S>                                                 <C>            <C>                <C>
REVENUE                                             $    --        $     --           $      --
------------------------------------------------------------------------------------------------------

EXPENSES
    Bank charges                                             75          --                     75
    Investor relations                                      741          --                    741
    Management and consulting fees                       82,328          --                 82,328
    Office and miscellaneous                                271             418                689
    Professional fees                                    24,068           2,832             26,900
    Regulatory and share transfer
        fees                                                457           1,943              2,400
    Rent and occupancy costs                              1,378           1,698              3,076
    Telephone                                             3,600             150              3,750
    Travel                                               --                 292                292

------------------------------------------------------------------------------------------------------
                                                        112,918           7,333            120,251
------------------------------------------------------------------------------------------------------

LOSS FROM OPERATIONS                                  (112,918)         (7,333)          (120,251)

    Interest income                                         185          --                    185

------------------------------------------------------------------------------------------------------
NET LOSS                                            $ (112,733)    $    (7,333)       $  (120,066)
======================================================================================================

Loss per share (Note 2(f))                          $    (0.01)    $       0.00
====================================================================================================

Weighted average number of shares outstanding        16,230,760      16,230,760
======================================================================================================
</TABLE>


The accompanying notes are an integral part of these financial statements.

                                       F-3

<PAGE>

LARREA BIOSCIENCES CORPORATION

(FORMERLY SONIC MEDIA CORP.)
(A DEVELOPMENT STAGE COMPANY)

STATEMENTS OF STOCKHOLDERS' EQUITY

<TABLE>
<CAPTION>
---------------------------------------------------------------------------------------------------------
FOR THE YEAR ENDED APRIL 30, 2004
---------------------------------------------------------------------------------------------------------
                                                                              Deficit
                                       Common stock                         Accumulated
                               -------------------------     Additional        During           Total
                                 Number                       Paid-in       Development     Stockholders'
                               of Shares         Amount       Capital          Stage            Equity
---------------------------------------------------------------------------------------------------------
<S>                            <C>             <C>            <C>           <C>              <C>
Issue of common stock for
    cash on organization of
    the Company                 4,000,000      $     400      $     100     $        --      $      500
Issue of common stock for
    cash                          997,040            100         99,604              --          99,704
Net loss for the period                --             --             --          (7,333)         (7,333)
---------------------------------------------------------------------------------------------------------
Balance April 30, 2003          4,997,040            500         99,704          (7,333)         92,871
Common stock returned to
    treasury                   (2,500,000)          (250)           250              --              --
Stock split 6.5 for 1          13,733,720          1,373         (1,373)             --              --
Net loss for the period                --             --             --        (112,733)       (112,733)
---------------------------------------------------------------------------------------------------------

Balance April 30, 2004         16,230,760      $   1,623      $  98,581     $  (120,066)     $  (19,862)
=========================================================================================================
</TABLE>


The accompanying notes are an integral part of these financial statements.

                                       F-4

<PAGE>

LARREA BIOSCIENCES CORPORATION

(FORMERLY SONIC MEDIA CORP.)
(A DEVELOPMENT STAGE COMPANY)

STATEMENTS OF CASH FLOWS

<TABLE>
<CAPTION>
-------------------------------------------------------------------------------------------------------------
                                                                                            PERIOD FROM
                                                                                      MAY 1, 2002 (INCEPTION)
                                                                                           TO APRIL 30,
FOR THE YEARS ENDED APRIL 30,                                 2004           2003               2004
-------------------------------------------------------------------------------------------------------------
<S>                                                        <C>            <C>                <C>
CASH FLOWS (USED IN) PROVIDED BY:

OPERATING ACTIVITIES
    Net loss                                               $(112,733)     $  (7,333)         $(120,066)
    Adjustments for items not affecting cash:
        Accounts payable and accrued liabilities              13,426          6,574             20,000
-------------------------------------------------------------------------------------------------------------
                                                             (99,307)          (759)          (100,066)
-------------------------------------------------------------------------------------------------------------
FINANCING ACTIVITIES
    Common stock issued for cash                                  --        100,204            100,204
-------------------------------------------------------------------------------------------------------------
INCREASE (DECREASE) IN CASH                                  (99,307)        99,445                138

CASH, beginning                                               99,445             --                 --
-------------------------------------------------------------------------------------------------------------
CASH, ending                                               $     138      $  99,445          $     138
=============================================================================================================

SUPPLEMENTAL INFORMATION Cash paid during the year to:
    Interest                                               $      --      $      --          $      --
    Income taxes                                           $      --      $      --          $      --
</TABLE>


The accompanying notes are an integral part of these financial statements.

                                       F-5

<PAGE>

LARREA BIOSCIENCES CORPORATION
NOTES TO THE FINANCIAL STATEMENTS
(FORMERLY SONIC MEDIA CORP.)
(A DEVELOPMENT STAGE COMPANY)

APRIL 30, 2004
--------------------------------------------------------------------------------

1.   ORGANIZATION AND DEVELOPMENT STAGE ACTIVITIES AND GOING CONCERN

     The Company  changed its name from Sonic Media Corp. to Larrea  Biosciences
     Corporation on June 1, 2004.

     The Company was  incorporated  under the laws of the State of Nevada on May
     1, 2002. The Company is focusing its operations on manufacturing, licensing
     and distributing "Green" pharmaceuticals. The Company has not yet generated
     business  from  these  principal  business   activities  and  is  therefore
     considered to be in the development stage.

     These  financial  statements have been prepared on a going concern basis in
     accordance with United States generally accepted accounting principles. The
     going  concern basis of  presentation  assumes the Company will continue in
     operation  throughout the next fiscal year and into the foreseeable  future
     and will be able to realize its assets and  discharge its  liabilities  and
     commitments in the normal course of business. Certain conditions, discussed
     below,  currently exist which raise  substantial doubt upon the validity of
     this  assumption.  The financial  statements do not include any adjustments
     that might result from the outcome of this uncertainty.

     As of April 30, 2004,  the Company is considered  to be in the  development
     stage as the Company has not generated revenues from its principal business
     activities. The Company's future operations are dependent upon it's ability
     to  obtain  third  party  financing  in the  form of debt  and  equity  and
     ultimately  to generate  future  profitable  operations  or income from its
     operations.  The Company is  currently  seeking  additional  funds  through
     future debt or equity  financing to offset  future cash flow  deficiencies.
     Such  financing  may not be available or may not be available on reasonable
     terms.  The  resolution  of this going  concern  issue is  dependent on the
     realization of management's plans. If management is unsuccessful in raising
     future debt or equity financing,  the Company will be required to liquidate
     assets and curtail or possibly cease operations.

2.   SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

     The  financial  statements  of the Company have been prepared in accordance
     with accounting principles generally accepted in the United States. Because
     a precise  determination  of many assets and  liabilities is dependent upon
     future  events,  the  preparation  of  financial  statements  for a  period
     necessarily  involves  the use of  estimates  which  have been  made  using
     careful judgement.

     The financial  statements  have,  in  management's  opinion,  been properly
     prepared within  reasonable  limits of materiality and within the framework
     of the accounting policies summarized below:

     (a) Cash and cash equivalents

         The Company considers all short-term investments, including investments
         in certificates  of deposit,  with a maturity date at purchase of three
         months or less to be cash equivalents.

     (b) Revenue recognition

         Revenue is recognized on the sale and transfer of goods and services.

     (c) Foreign currencies

         The  functional  currency of the Company is the United  States  dollar.
         Transactions  in foreign  currencies are translated  into United States
         dollars at the rates in effect on the transaction date.  Exchange gains
         or losses  arising on  translation  or settlement  of foreign  currency
         denominated monetary items are included in the statement of operations.


                                       F-6
<PAGE>

LARREA BIOSCIENCES CORPORATION
NOTES TO THE FINANCIAL STATEMENTS
(FORMERLY SONIC MEDIA CORP.)
(A DEVELOPMENT STAGE COMPANY)

APRIL 30, 2004
--------------------------------------------------------------------------------


2.   SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, CONTINUED

     (d) Financial instruments

         The  Company's  financial  instruments  consist  of cash  and  accounts
         payable and accrued liabilities.

         Management  is of the  opinion  that  the  Company  is not  subject  to
         significant  interest,  currency  or  credit  risks  on  the  financial
         instruments  included in these  financial  statements.  The fair market
         values  of  these  financial  instruments  approximate  their  carrying
         values.

     (e) Income taxes

         The Company  follows the asset and liability  method of accounting  for
         income taxes.  Under this method,  current taxes are recognized for the
         estimated income taxes payable for the current period.

         Deferred  income taxes are provided  based on the estimated  future tax
         effects of temporary  differences  between financial statement carrying
         amounts of assets and  liabilities  and their  respective  tax bases as
         well as the benefit of losses available to be carried forward to future
         years for tax purposes.

         Deferred  tax assets and  liabilities  are measured  using  enacted tax
         rates  that are  expected  to apply to  taxable  income in the years in
         which  those  temporary  differences  are  expected  to be  covered  or
         settled.  The effect on deferred tax assets and liabilities of a change
         in tax rates is  recognized  in  operations in the period that includes
         the enactment date. A valuation  allowance is recorded for deferred tax
         assets when it is more likely  than not that such  deferred  tax assets
         will not be realized.

     (f) Loss per share

         Basic  loss per  share is  computed  by  dividing  loss for the  period
         available  to common  stockholders  by the weighted  average  number of
         common stock outstanding during the periods.  Diluted loss per share is
         computed  using  the  weighted  average  number  of  common  stock  and
         potentially  dilutive common stock  issuances,  outstanding  during the
         period. As the Company has a net loss in each of the periods presented,
         basic and diluted loss per share are the same.

     (g) Recent accounting pronouncements

         In January 2003,  the Financial  Accounting  Standards  Board  ("FASB")
         issued Financial  Interpretation  No. 46 ("FIN 46"),  "Consolidation of
         Variable  Interest  Entities",  which  addresses the  consolidation  of
         variable interest entities  (formerly  referred to as  "Special-Purpose
         Entities").  The  Interpretation  is generally in effect for interim or
         annual periods  beginning  after December 15, 2003. The adoption of FIN
         No. 46 had no material impact on the Company's  financial  condition or
         results of operations.

         In May 2003,  the FASB  issued  SFAS No. 150  "Accounting  for  Certain
         Financial  Instruments  with  Characteristics  of Both  Liabilities and
         Equity".  SFAS No. 150  requires  that  certain  financial  instruments
         issued in the form of shares that are mandatorily redeemable as well as
         certain other financial instruments be classified as a liability in the
         financial  statements.   SFAS  No.  150  was  effective  for  financial
         instruments  entered into or modified  after May 31, 2003.  The Company
         has reviewed the  requirements  of SFAS No. 150 and has determined that
         it did not have an impact on its  financial  condition  or  results  of
         operations.

     (h) Comparative figures

         Certain  comparative  figures have been  reclassified to conform to the
         basis of presentation adopted for the current year.


                                       F-7
<PAGE>

LARREA BIOSCIENCES CORPORATION
NOTES TO THE FINANCIAL STATEMENTS
(FORMERLY SONIC MEDIA CORP.)
(A DEVELOPMENT STAGE COMPANY)

APRIL 30, 2004
--------------------------------------------------------------------------------


3.   STOCKHOLDERS' EQUITY

     Common stock offering:

         During  2003,  the Company  completed a private  placement  offering of
         4,000,000  common  shares to its officers and  directors for $500 and a
         registered public offering of 997,040 common shares for $99,704.

         On January 16, 2004,  the  Company's  officers and  directors  returned
         2,500,000 common shares to the Company's treasury.

         On January 23, 2004, the Company declared a 6.5 for 1 stock split.


4.   RELATED PARTY TRANSACTIONS

     (a) Accounts payable include $NIL (2003 - $4,719) owing to a former officer
and director of the Company.

     (b) During the year,  former  directors of the Company  returned  2,500,000
         (pre-split) common shares to the Company's treasury.


5.   INCOME TAXES

     Deferred tax assets and liabilities:

                                                      2004             2003
--------------------------------------------------------------------------------
     Deferred tax assets:
        Operating loss carry-forwards              $  40,823        $  2,493
        Valuation allowance                          (40,823)         (2,493)
--------------------------------------------------------------------------------
     Net deferred tax asset                        $    --          $    --
================================================================================

     Management believes that it is not more likely than not that it will create
     sufficient taxable income sufficient to realize its deferred tax assets. It
     is reasonably  possible these  estimates  could change due to future income
     and the timing and manner of the reversal of deferred tax liabilities.  Due
     to its losses, the Company has no income tax expense.

     The Company has operating  loss  carry-forwards  for income tax purposes at
     April 30, 2004 of approximately $120,067.  Operating losses begin to expire
     in fiscal year 2023.


6.   COMMITMENTS

     Pursuant to the terms of a stock  purchase  agreement  ("Agreement")  dated
     March 26,  2004,  the Company has agreed to purchase  all of the issued and
     outstanding  capital  stock  of  Global  Botanics,   Inc.   ("Global"),   a
     corporation organized under the laws of Niue.

     Global's major assets consist of four United States patents relating to the
     production and use of proprietary  extracts from the plant species  'Larrea
     Tridentata'.  These patents were acquired by Global for  $1,200,000  from a
     company which is controlled by a director of the Company.

     The  terms  of  the  agreement  require  the  Company  to  issue  3,500,000
     restricted  common shares to the shareholders of Global.  These shares were
     issued August 5, 2004.


                                       F-8